研究者Shana ...

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network ...

Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

Hayashi. The team assessed the soluble forms of immune checkpoint molecules, PD-L1, PD-1, and CTLA-4 in the blood samples of patients with advanced NSCLC before PD-1/PD-L1 blockade therapy.